BIO-TECHNE Corp vs Under Armour Inc Class A — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Under Armour Inc Class A trades at $5.39 (market cap $2.57B). The key difference: BIO-TECHNE Corp is far larger — about 4.4× Under Armour Inc Class A's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| TECH | UAA | |
|---|---|---|
Market Cap | $11.24B | $2.57B |
Sector | Health | Consumer Cyclical |
52-Week High | $72.29 | $8.14 |
52-Week Low | $43.31 | $4.17 |
Enterprise Value | $11.32B | $3.55B |
Dividend Yield | 0.44% | — |
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Under Armour (UAA) trades at $6.11, down 4.38% today, reflecting ongoing challenges. The stock shows a bearish technical trend with key support at $6. Recent Q2 2026 earnings beat expectations with EPS of $0.05 versus $0.02, but revenue declined year-over-year. Financials reveal negative net income margin of -9.98% and weak cash flow, with net cash outflow of $361.87 million in 2025. Analysts maintain a cautious stance amid soft demand in key markets.
The outlook remains challenging due to persistent revenue declines and profitability issues. Investment opportunities hinge on successful execution of turnaround strategies, but risks include intense competition and macroeconomic pressures. With a consensus price target of $5.96 below the current price, Wall Street sentiment is neutral to bearish, emphasizing the need for improved fundamentals to drive recovery.
Trailing returns across standard periods
Latest headlines on both assets
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →